

Xavier Forns

List of Publications by Citations

Source: <https://exaly.com/author-pdf/6313836/xavier-forns-publications-by-citations.pdf>

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

303 papers	16,165 citations	60 h-index	121 g-index
353 ext. papers	18,306 ext. citations	5.9 avg, IF	6.23 L-index

#	Paper	IF	Citations
303	Non-invasive evaluation of liver fibrosis using transient elastography. <i>Journal of Hepatology</i> , 2008 , 48, 835-47	13.4	964
302	ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. <i>New England Journal of Medicine</i> , 2014 , 370, 1973-82	59.2	754
301	Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. <i>Hepatology</i> , 2002 , 36, 986-92	11.2	753
300	Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. <i>Journal of Hepatology</i> , 2016 , 65, 719-726	13.4	709
299	Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. <i>Hepatology</i> , 1994 , 20, 1495-501	11.2	413
298	Hepatitis C virus kinetics during and immediately after liver transplantation. <i>Hepatology</i> , 2002 , 35, 680-711	11.2	411
297	Hospital admission is a relevant source of hepatitis C virus acquisition in Spain. <i>Journal of Hepatology</i> , 2008 , 48, 20-7	13.4	362
296	Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. <i>Lancet Infectious Diseases</i> , 2016 , 16, 685-697	25.5	346
295	An interferon-free antiviral regimen for HCV after liver transplantation. <i>New England Journal of Medicine</i> , 2014 , 371, 2375-82	59.2	335
294	Transient elastography for diagnosis of advanced fibrosis and portal hypertension in patients with hepatitis C recurrence after liver transplantation. <i>Liver Transplantation</i> , 2006 , 12, 1791-8	4.5	315
293	Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. <i>Gastroenterology</i> , 2007 , 132, 1746-56	13.3	299
292	A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. <i>Liver International</i> , 2011 , 31 Suppl 2, 30-60	7.9	293
291	Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. <i>Gastroenterology</i> , 2004 , 127, 1347-55	13.3	284
290	Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. <i>Gastroenterology</i> , 2015 , 148, 108-17	13.3	280
289	Noninvasive assessment of liver fibrosis. <i>Hepatology</i> , 2011 , 53, 325-35	11.2	278
288	Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. <i>Gastroenterology</i> , 2015 , 148, 100-107.e1	13.3	266
287	Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. <i>Journal of Hepatology</i> , 2003 , 39, 389-96	13.4	248

286	Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. <i>Lancet Infectious Diseases, The</i> , 2017 , 17, 1062-1068	25.5	238
285	Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation. <i>Hepatology</i> , 2006 , 43, 492-9	11.2	238
284	Interferon-induced depression in chronic hepatitis C: a systematic review and meta-analysis. <i>Journal of Clinical Psychiatry</i> , 2012 , 73, 1128-38	4.6	216
283	Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. <i>Gastroenterology</i> , 2014 , 146, 1669-79.e3	13.3	214
282	Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases. <i>Medicine (United States)</i> , 2011 , 90, 359-371	1.8	203
281	Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation. <i>Hepatology</i> , 2015 , 61, 1485-94	11.2	183
280	Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: A retrospective study. <i>Journal of Hepatology</i> , 2009 , 50, 719-28	13.4	167
279	Effects of All-Oral Anti-Viral Therapy on HVPG and Systemic Hemodynamics in Patients With Hepatitis C Virus-Associated Cirrhosis. <i>Gastroenterology</i> , 2017 , 153, 1273-1283.e1	13.3	164
278	Hepatitis C recurrence is more severe after living donor compared to cadaveric liver transplantation. <i>Hepatology</i> , 2004 , 40, 699-707	11.2	158
277	Viral hepatitis in liver transplantation. <i>Gastroenterology</i> , 2012 , 142, 1373-1383.e1	13.3	156
276	Hepatitis C virus lacking the hypervariable region 1 of the second envelope protein is infectious and causes acute resolving or persistent infection in chimpanzees. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000 , 97, 13318-23	11.5	127
275	Vaccination of chimpanzees with plasmid DNA encoding the hepatitis C virus (HCV) envelope E2 protein modified the infection after challenge with homologous monoclonal HCV. <i>Hepatology</i> , 2000 , 32, 618-25	11.2	126
274	Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent. <i>Journal of Hepatology</i> , 2015 , 63, 564-72	13.4	123
273	ARFI, FibroScan, ELF, and their combinations in the assessment of liver fibrosis: a prospective study. <i>Journal of Hepatology</i> , 2012 , 57, 281-7	13.4	123
272	Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection. <i>Hepatology</i> , 2018 , 68, 1298-1307	11.2	121
271	Ghrelin attenuates hepatocellular injury and liver fibrogenesis in rodents and influences fibrosis progression in humans. <i>Hepatology</i> , 2010 , 51, 974-85	11.2	114
270	Quasispecies in viral persistence and pathogenesis of hepatitis C virus. <i>Trends in Microbiology</i> , 1999 , 7, 402-10	12.4	112
269	Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C. <i>Gastroenterology</i> , 2011 , 140, 459-468.e1; quiz e14	13.3	111

268	Systemic autoimmune diseases in patients with hepatitis C virus infection: characterization of 1020 cases (The HISPAMEC Registry). <i>Journal of Rheumatology</i> , 2009 , 36, 1442-8	4.1	107
267	Hepatitis C virus (HCV) genotypes in Spanish patients with HCV infection: relationship between HCV genotype 1b, cirrhosis and hepatocellular carcinoma. <i>Journal of Hepatology</i> , 1997 , 27, 959-65	13.4	107
266	Liver stiffness identifies two different patterns of fibrosis progression in patients with hepatitis C virus recurrence after liver transplantation. <i>Hepatology</i> , 2010 , 51, 23-34	11.2	103
265	The prognostic relevance of the nonstructural 5A gene interferon sensitivity determining region is different in infections with genotype 1b and 3a isolates of hepatitis C virus. <i>Journal of Infectious Diseases</i> , 1998 , 177, 839-47	7	101
264	Effects of losartan on hepatic expression of nonphagocytic NADPH oxidase and fibrogenic genes in patients with chronic hepatitis C. <i>American Journal of Physiology - Renal Physiology</i> , 2009 , 297, G726-34	5.1	95
263	Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGE. <i>Clinical Infectious Diseases</i> , 2016 , 62, 32-6	11.6	85
262	Portal pressure and liver stiffness measurements in the prediction of fibrosis regression after sustained virological response in recurrent hepatitis C. <i>Hepatology</i> , 2018 , 67, 1683-1694	11.2	83
261	Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension. <i>Journal of Viral Hepatitis</i> , 2017 , 24, 823-831	3.4	80
260	Efficacy and tolerability of interferon-free antiviral therapy in kidney transplant recipients with chronic hepatitis C. <i>Journal of Hepatology</i> , 2017 , 66, 718-723	13.4	80
259	Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antivirals. <i>Journal of Hepatology</i> , 2020 , 72, 472-480	13.4	79
258	Life-threatening cryoglobulinemia: clinical and immunological characterization of 29 cases. <i>Seminars in Arthritis and Rheumatism</i> , 2006 , 36, 189-96	5.3	78
257	Clinical outcomes of patients undergoing antiviral therapy while awaiting liver transplantation. <i>Journal of Hepatology</i> , 2017 , 67, 1168-1176	13.4	77
256	Severe autoimmune cytopenias in treatment-naïve hepatitis C virus infection: clinical description of 35 cases. <i>Medicine (United States)</i> , 2003 , 82, 87-96	1.8	76
255	Virologic, Clinical, and Immune Response Outcomes of Patients With Hepatitis C Virus-Associated Cryoglobulinemia Treated With Direct-Acting Antivirals. <i>Clinical Gastroenterology and Hepatology</i> , 2017 , 15, 575-583.e1	6.9	75
254	Assessment of liver fibrosis before and after antiviral therapy by different serum marker panels in patients with chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2011 , 33, 138-48	6.1	71
253	Donor and recipient IL28B polymorphisms in HCV-infected patients undergoing antiviral therapy before and after liver transplantation. <i>American Journal of Transplantation</i> , 2011 , 11, 1051-7	8.7	71
252	Beneficial effect of angiotensin-blocking agents on graft fibrosis in hepatitis C recurrence after liver transplantation. <i>Transplantation</i> , 2004 , 78, 686-91	1.8	68
251	The molecular biology of hepatitis C virus. Genotypes and quasispecies. <i>Clinics in Liver Disease</i> , 1999 , 3, 693-716, vii	4.6	67

250	High-resolution hepatitis C virus subtyping using NS5B deep sequencing and phylogeny, an alternative to current methods. <i>Journal of Clinical Microbiology</i> , 2015 , 53, 219-26	9.7	64
249	Insulin resistance and response to telaprevir plus peginterferon α and ribavirin in treatment-naïve patients infected with HCV genotype 1. <i>Gut</i> , 2012 , 61, 1473-80	19.2	61
248	Second hepatitis C replication compartment indicated by viral dynamics during liver transplantation. <i>Journal of Hepatology</i> , 2005 , 42, 491-8	13.4	61
247	A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C. <i>Journal of Viral Hepatitis</i> , 2012 , 19 Suppl 2, 1-26	3.4	60
246	HCV-induced immune responses influence the development of operational tolerance after liver transplantation in humans. <i>Science Translational Medicine</i> , 2014 , 6, 242ra81	17.5	60
245	Liver Cancer Emergence Associated with Antiviral Treatment: An Immune Surveillance Failure?. <i>Seminars in Liver Disease</i> , 2017 , 37, 109-118	7.3	59
244	Infection with a novel human DNA virus (TTV) has no pathogenic significance in patients with liver diseases. <i>Journal of Hepatology</i> , 1999 , 30, 1028-34	13.4	59
243	The challenge of developing a vaccine against hepatitis C virus. <i>Journal of Hepatology</i> , 2002 , 37, 684-95	13.4	58
242	Treatment options in patients with decompensated cirrhosis, pre- and post-transplantation. <i>Journal of Hepatology</i> , 2014 , 61, S120-31	13.4	57
241	Serum fibrosis markers identify patients with mild and progressive hepatitis C recurrence after liver transplantation. <i>Gastroenterology</i> , 2010 , 138, 147-58.e1	13.3	56
240	Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension. <i>Journal of Hepatology</i> , 2020 , 73, 1415-1424	13.4	55
239	Dynamics of hepatitis C virus NS5A quasispecies during interferon and ribavirin therapy in responder and non-responder patients with genotype 1b chronic hepatitis C. <i>Journal of General Virology</i> , 2005 , 86, 1067-1075	4.9	55
238	The efficacy of direct anti-HCV drugs improves early post-liver transplant survival and induces significant changes in waiting list composition. <i>Journal of Hepatology</i> , 2018 , 69, 11-17	13.4	54
237	G02 : Ledipasvir/sofosbuvir with ribavirin is safe and efficacious in decompensated and post liver transplantation patients with HCV infection: Preliminary results of the prospective solar 2 trial. <i>Journal of Hepatology</i> , 2015 , 62, S187-S188	13.4	53
236	Life-Threatening Cryoglobulinemic Patients With Hepatitis C: Clinical Description and Outcome of 279 Patients. <i>Medicine (United States)</i> , 2013 , 92, 273-284	1.8	53
235	Peginterferon plus ribavirin and sustained virological response in HCV-related cirrhosis: outcomes and factors predicting response. <i>American Journal of Gastroenterology</i> , 2010 , 105, 2164-72; quiz 2173	0.7	53
234	Retransplantation in patients with hepatitis C recurrence after liver transplantation. <i>Journal of Hepatology</i> , 2010 , 53, 962-70	13.4	52
233	How Escherichia coli can bias the results of molecular cloning: preferential selection of defective genomes of hepatitis C virus during the cloning procedure. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1997 , 94, 13909-14	11.5	52

232	Long-Term Outcomes of Patients With HCV-Associated Cryoglobulinemic Vasculitis After Virologic Cure. <i>Gastroenterology</i> , 2018 , 155, 311-315.e6	13.3	51
231	Disulfiram-induced hepatitis. Report of four cases and review of the literature. <i>Journal of Hepatology</i> , 1994 , 21, 853-7	13.4	51
230	Safety, pharmacokinetics and antiviral effect of BILB 1941, a novel hepatitis C virus RNA polymerase inhibitor, after 5 days oral treatment. <i>Antiviral Therapy</i> , 2009 , 14, 23-32	1.6	50
229	Studies of hepatitis C virus in chimpanzees and their importance for vaccine development. <i>Intervirology</i> , 2001 , 44, 132-42	2.5	49
228	Longitudinal liver stiffness assessment in patients with chronic hepatitis C undergoing antiviral therapy. <i>PLoS ONE</i> , 2012 , 7, e47715	3.7	48
227	Evolution of hepatitis C virus quasispecies immediately following liver transplantation. <i>Liver Transplantation</i> , 2004 , 10, 1131-9	4.5	48
226	O68 SOFOSBUVIR AND RIBAVIRIN FOR THE TREATMENT OF CHRONIC HCV WITH CIRRHOSIS AND PORTAL HYPERTENSION WITH AND WITHOUT DECOMPENSATION: EARLY VIROLOGIC RESPONSE AND SAFETY. <i>Journal of Hepatology</i> , 2014 , 60, S28	13.4	47
225	MAGELLAN-2: safety and efficacy of glecaprevir/pibrentasvir in liver or renal transplant adults with chronic hepatitis C genotype 1B infection. <i>Journal of Hepatology</i> , 2017 , 66, S90-S91	13.4	47
224	DNA immunization of mice and macaques with plasmids encoding hepatitis C virus envelope E2 protein expressed intracellularly and on the cell surface. <i>Vaccine</i> , 1999 , 17, 1992-2002	4.1	47
223	Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis. <i>Gastroenterology</i> , 2018 , 155, 1120-1127.e4	13.3	47
222	Quality of life, major medical complications and hospital service utilization in patients with primary biliary cirrhosis after liver transplantation. <i>Journal of Hepatology</i> , 1996 , 25, 129-34	13.4	46
221	Association Between Severe Portal Hypertension and Risk of Liver Decompensation in Patients With Hepatitis C, Regardless of Response to Antiviral Therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2015 , 13, 1846-1853.e1	6.9	45
220	Hepatitis C virus compartmentalization and infection recurrence after liver transplantation. <i>American Journal of Transplantation</i> , 2009 , 9, 1591-601	8.7	45
219	Nosocomial transmission of HCV in the liver unit of a tertiary care center. <i>Hepatology</i> , 2005 , 41, 115-22	11.2	45
218	High prevalence of TT virus (TTV) infection in patients on maintenance hemodialysis: Frequent mixed infections with different genotypes and lack of evidence of associated liver disease. <i>Journal of Medical Virology</i> , 1999 , 59, 313-317	19.7	45
217	Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules. <i>Journal of Hepatology</i> , 2019 , 70, 874-884	13.4	44
216	Sofosbuvir/velpatasvir for 12 weeks in genotype 1-4 HCV-infected liver transplant recipients. <i>Journal of Hepatology</i> , 2018 , 69, 603-607	13.4	44
215	Hepatitis G virus infection in chronic hepatitis C: frequency, features and response to interferon therapy. <i>Journal of Hepatology</i> , 1997 , 26, 787-93	13.4	44

214	Virology and pathogenesis of hepatitis C virus recurrence. <i>Liver Transplantation</i> , 2008 , 14 Suppl 2, S27-35	4.5	44
213	Hepatitis C virus envelope protein E2 binds to CD81 of tamarins. <i>Virology</i> , 2000 , 277, 358-67	3.6	43
212	Long-term follow-up of chronic hepatitis C in patients diagnosed at a tertiary-care center. <i>Journal of Hepatology</i> , 2001 , 35, 265-71	13.4	43
211	Comparative study of three methods for genotyping hepatitis C virus strains in samples from Spanish patients. <i>Journal of Clinical Microbiology</i> , 1996 , 34, 2516-21	9.7	43
210	Incidence and risk factors of hepatitis C virus infection in a haemodialysis unit. <i>Nephrology Dialysis Transplantation</i> , 1997 , 12, 736-40	4.3	42
209	Development and validation of two models for early prediction of response to therapy in genotype 1 chronic hepatitis C. <i>Hepatology</i> , 2006 , 43, 72-80	11.2	41
208	Hepatitis B reactivation in patients with chronic hepatitis C undergoing anti-viral therapy with an interferon-free regimen. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 45, 1156-1161	6.1	39
207	Liver stiffness 1 year after transplantation predicts clinical outcomes in patients with recurrent hepatitis C. <i>American Journal of Transplantation</i> , 2014 , 14, 375-83	8.7	39
206	High amino acid variability within the NS5A of hepatitis C virus (HCV) is associated with hepatocellular carcinoma in patients with HCV-1b-related cirrhosis. <i>Hepatology</i> , 2001 , 34, 158-67	11.2	38
205	Permanent response to alpha-interferon therapy in chronic hepatitis C is preceded by rapid clearance of HCV-RNA from serum. <i>Journal of Hepatology</i> , 1996 , 25, 827-32	13.4	38
204	Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with hepatitis C virus genotype 1b infection without cirrhosis (GARNET): a single-arm, open-label, phase 3b trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2017 , 2, 494-500	18.8	37
203	Intravenous silibinin monotherapy shows significant antiviral activity in HCV-infected patients in the peri-transplantation period. <i>Journal of Hepatology</i> , 2013 , 58, 415-20	13.4	37
202	Management of ascites and renal failure in cirrhosis. <i>Seminars in Liver Disease</i> , 1994 , 14, 82-96	7.3	36
201	Hepatitis G virus infection in a haemodialysis unit: prevalence and clinical implications. <i>Nephrology Dialysis Transplantation</i> , 1997 , 12, 956-60	4.3	35
200	Characterization of modified hepatitis C virus E2 proteins expressed on the cell surface. <i>Virology</i> , 2000 , 274, 75-85	3.6	34
199	Reactivation of Herpesvirus in Patients With Hepatitis C Treated With Direct-Acting Antiviral Agents. <i>Clinical Gastroenterology and Hepatology</i> , 2016 , 14, 1662-1666.e1	6.9	34
198	Neutralization resistance of hepatitis C virus can be overcome by recombinant human monoclonal antibodies. <i>Hepatology</i> , 2013 , 58, 1587-97	11.2	33
197	DNA-based vaccination against hepatitis C virus (HCV): effect of expressing different forms of HCV E2 protein and use of CpG-optimized vectors in mice. <i>Vaccine</i> , 2002 , 20, 3263-71	4.1	33

- 196 Prevention and treatment of hepatitis C virus recurrence after liver transplantation. *Journal of Hepatology*, **2004**, 41, 2-10 13.4 32
- 195 Hepatitis G virus infection in chronic liver disease. *Gut*, **1998**, 42, 107-11 19.2 32
- 194 Low risk of hepatitis B reactivation in patients with severe COVID-19 who receive immunosuppressive therapy. *Journal of Viral Hepatitis*, **2021**, 28, 89-94 3.4 32
- 193 Interferon-free regimens in the liver-transplant setting. *Seminars in Liver Disease*, **2014**, 34, 58-71 7.3 31
- 192 Hepatitis C virus superinfection of liver grafts: a detailed analysis of early exclusion of non-dominant virus strains. *Journal of General Virology*, **2010**, 91, 1183-8 4.9 31
- 191 Prophylactic antidepressant treatment of interferon-induced depression in chronic hepatitis C: a systematic review and meta-analysis. *Journal of Clinical Psychiatry*, **2014**, 75, e1113-21 4.6 30
- 190 Hepatitis C virus receptors claudin-1 and occludin after liver transplantation and influence on early viral kinetics. *Hepatology*, **2011**, 53, 1436-45 11.2 29
- 189 Longevity and replenishment of human liver-resident memory T cells and mononuclear phagocytes. *Journal of Experimental Medicine*, **2020**, 217, 16.6 27
- 188 New concepts of sofosbuvir-based treatment regimens in patients with hepatitis C. *Gut*, **2014**, 63, 207-15 9.2 26
- 187 Hepatitis A outbreak in Barcelona among men who have sex with men (MSM), January-June 2017: A hospital perspective. *Liver International*, **2018**, 38, 588-593 7.9 25
- 186 Usefulness of liver stiffness measurement during acute cellular rejection in liver transplantation. *Liver Transplantation*, **2016**, 22, 298-304 4.5 25
- 185 How hepatitis C virus modifies the immunological profile of Sjögren syndrome: analysis of 783 patients. *Arthritis Research and Therapy*, **2015**, 17, 250 5.7 24
- 184 O001 : C-salvage: grazoprevir (GZR; MK-5172), elbasvir (EBR; MK-8742) and ribavirin (RBV) for chronic hcv-genotype 1 (GT1) infection after failure of direct-acting antiviral (DAA) therapy. *Journal of Hepatology*, **2015**, 62, S190 13.4 23
- 183 Influence of the genetic heterogeneity of the ISDR and PePHD regions of hepatitis C virus on the response to interferon therapy in chronic hepatitis C. *Journal of Medical Virology*, **2001**, 65, 35-44 19.7 22
- 182 LP13 : Effect of long term viral suppression with sofosbuvir + ribavirin on hepatic venous pressure gradient in HCV-infected patients with cirrhosis and portal hypertension. *Journal of Hepatology*, **2015**, 62, S269-S270 13.4 21
- 181 O62 SOFOSBUVIR COMPASSIONATE USE PROGRAM FOR PATIENTS WITH SEVERE RECURRENT HEPATITIS C INCLUDING FIBROSING CHOLESTATIC HEPATITIS FOLLOWING LIVER TRANSPLANTATION. *Journal of Hepatology*, **2014**, 60, S26 13.4 21
- 180 Hepatitis G virus infection in fulminant hepatic failure. *Gut*, **1997**, 41, 696-9 19.2 21
- 179 Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis. *Gut*, **2021**, 19.2 21

178	Interferon-Free Therapy in Elderly Patients With Advanced Liver Disease. <i>American Journal of Gastroenterology</i> , 2017 , 112, 1400-1409	0.7	20
177	P1232 SOFOSBUVIR AND RIBAVIRIN FOR THE TREATMENT OF RECURRENT HEPATITIS C INFECTION AFTER LIVER TRANSPLANTATION: RESULTS OF A PROSPECTIVE, MULTICENTER STUDY. <i>Journal of Hepatology</i> , 2014 , 60, S499	13.4	20
176	Cryoglobulinaemia associated with hepatitis C virus: influence of HCV genotypes, HCV-RNA viraemia and HIV coinfection. <i>Journal of Viral Hepatitis</i> , 2007 , 14, 736-42	3.4	20
175	HCV virological assessment. <i>Journal of Hepatology</i> , 2006 , 44, S35-9	13.4	20
174	Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure. <i>Antiviral Research</i> , 2020 , 174, 104694	10.8	20
173	Anti-viral therapy can be delayed or avoided in a significant proportion of HBeAg-negative Caucasian patients in the Grey Zone. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 47, 1397-1408	6.1	19
172	O114 RESULTS OF THE PHASE 2 STUDY M12-999: INTERFERON-FREE REGIMEN OF ABT-450/R/ABT-267 + ABT-333 + RIBAVIRIN IN LIVER TRANSPLANT RECIPIENTS WITH RECURRENT HCV GENOTYPE 1 INFECTION. <i>Journal of Hepatology</i> , 2014 , 60, S47	13.4	19
171	HEV infection in two referral centers in Spain: epidemiology and clinical outcomes. <i>Journal of Clinical Virology</i> , 2015 , 63, 76-80	14.5	19
170	Clinical trial watch: reports from the AASLD Liver Meeting , Boston, November 2014. <i>Journal of Hepatology</i> , 2015 , 62, 1196-203	13.4	18
169	Viral Kinetics in Patients with Chronic Hepatitis C Treated with the Serine Protease Inhibitor Biln 2061. <i>Antiviral Therapy</i> , 2006 , 11, 371-376	1.6	18
168	Combinations of simple baseline variables accurately predict sustained virological response in patients with recurrent hepatitis C after liver transplantation. <i>Journal of Gastroenterology</i> , 2013 , 48, 762-9	6.9	17
167	Treatment of HCV infection in patients with advanced cirrhosis. <i>Hepatology</i> , 2004 , 40, 498	11.2	17
166	Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. <i>Hepatology</i> , 2002 , 36, 986-992	11.2	17
165	A Metabolomics Signature Linked To Liver Fibrosis In The Serum Of Transplanted Hepatitis C Patients. <i>Scientific Reports</i> , 2017 , 7, 10497	4.9	16
164	Interplay between basic residues of hepatitis C virus glycoprotein E2 with viral receptors, neutralizing antibodies and lipoproteins. <i>PLoS ONE</i> , 2012 , 7, e52651	3.7	16
163	Selective inhibition of hepatitis C virus infection by hydroxyzine and benztropine. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 3451-60	5.9	15
162	Antiviral treatment with sofosbuvir and simeprevir in a kidney transplant recipient with HCV-decompensated cirrhosis: viral eradication and removal from the liver transplant waiting list. <i>Transplant International</i> , 2015 , 28, 1345-9	3	15
161	PNPLA3 rs738409 causes steatosis according to viral & IL28B genotypes in hepatitis C. <i>Annals of Hepatology</i> , 2014 , 13, 356-363	3.1	15

160	Hepatitis C Virus RNA Persists in Liver Explants of Most Patients Awaiting Liver Transplantation Treated With an Interferon-Free Regimen. <i>Gastroenterology</i> , 2016 , 151, 633-636.e3	13.3	15
159	Viral and immune factors associated with successful treatment withdrawal in HBeAg-negative chronic hepatitis B patients. <i>Journal of Hepatology</i> , 2021 , 74, 1064-1074	13.4	15
158	Therapy. Statins and liver disease: from concern to 'wonder' drugs?. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2015 , 12, 320-1	24.2	14
157	Ombitasvir/paritaprevir/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopaenia and hypoalbuminaemia. <i>Liver International</i> , 2015 , 35, 2358-62	7.9	14
156	Determination of IL28B polymorphisms in liver biopsies obtained after liver transplantation. <i>Journal of Hepatology</i> , 2012 , 56, 355-8	13.4	14
155	Pre-treatment with prednisolone does not improve the efficacy of subsequent alpha interferon therapy in chronic hepatitis C. <i>Journal of Hepatology</i> , 2000 , 33, 135-41	13.4	14
154	Comparative study of a modified competitive RT-PCR and Amplicor HCV monitor assays for quantitation of hepatitis C virus RNA in serum. <i>Journal of Medical Virology</i> , 1999 , 58, 35-43	19.7	14
153	Influence of the genetic heterogeneity of the ISDR and PePHD regions of hepatitis C virus on the response to interferon therapy in chronic hepatitis C. <i>Journal of Medical Virology</i> , 2001 , 65, 35-44	19.7	14
152	Phylogenetic analysis of an epidemic outbreak of acute hepatitis C in HIV-infected patients by ultra-deep pyrosequencing. <i>Journal of Clinical Virology</i> , 2017 , 92, 42-47	14.5	13
151	P0774 : Ledipasvir/sofosbuvir with ribavirin is safe in >600 decompensated and post liver transplantation patients with HCV infection: An integrated safety analysis of the solar 1 and solar 2 trials. <i>Journal of Hepatology</i> , 2015 , 62, S620-S621	13.4	13
150	Simeprevir with peginterferon/ribavirin for treatment of chronic hepatitis C virus genotype 1 infection: pooled safety analysis from Phase IIb and III studies. <i>Journal of Viral Hepatitis</i> , 2015 , 22, 366-75	3.4	13
149	Sensitivity to antiviral therapy may change after liver transplantation in patients with chronic hepatitis C virus infection. <i>Journal of Viral Hepatitis</i> , 2006 , 13, 544-51	3.4	13
148	Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEEH). <i>Gastroenterología y Hepatología</i> , 2019 , 42, 579-592	0.9	13
147	Safety and efficacy of triple therapy with peginterferon, ribavirin and boceprevir within an early access programme in Spanish patients with hepatitis C genotype 1 with severe fibrosis: SVRw12 analysis. <i>Liver International</i> , 2015 , 35, 90-100	7.9	12
146	Liver transplant immunosuppression during the covid-19 pandemic. <i>Gastroenterología y Hepatología</i> , 2020 , 43, 457-463	0.9	12
145	Impact of comorbidities on patient outcomes after interferon-free therapy-induced viral eradication in hepatitis C. <i>Journal of Hepatology</i> , 2018 , 68, 940-948	13.4	12
144	Predicting the development of liver cirrhosis by simple modelling in patients with chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 43, 364-74	6.1	12
143	Lack of a 5.9 kDa peptide C-terminal fragment of fibrinogen α chain precedes fibrosis progression in patients with liver disease. <i>PLoS ONE</i> , 2014 , 9, e109254	3.7	12

142	Antiphospholipid syndrome during pegylated interferon alpha-2a therapy for chronic hepatitis C. <i>Digestive and Liver Disease</i> , 2009 , 41, e4-7	3.3	12
141	SARS-CoV-2 in patients on antiviral HBV and HCV therapy in Spain. <i>Journal of Hepatology</i> , 2020 , 73, 1262-1263	13.4	12
140	Clinico-biological characteristics and outcome of hepatitis C virus-positive patients with diffuse large B-cell lymphoma treated with immunochemotherapy. <i>Annals of Hematology</i> , 2017 , 96, 405-410	3	11
139	Severity of liver disease affects HCV kinetics in patients treated with intravenous silibinin monotherapy. <i>Antiviral Therapy</i> , 2015 , 20, 149-55	1.6	11
138	The addition of a protease inhibitor increases the risk of infections in patients with hepatitis C-related cirrhosis. <i>Journal of Hepatology</i> , 2015 , 62, 311-6	13.4	11
137	Early periportal sinusoidal fibrosis is an accurate marker of accelerated HCV recurrence after liver transplantation. <i>Journal of Hepatology</i> , 2014 , 61, 270-7	13.4	11
136	P1185 INTERIM SVR12 RESULTS FROM THE TELAPREVIR PHASE 3B REPLACE STUDY IN TREATMENT-NAIVE STABLE LIVER TRANSPLANT PATIENTS WITH GENOTYPE 1 HCV INFECTION. <i>Journal of Hepatology</i> , 2014 , 60, S481	13.4	11
135	Cell culture replication of a genotype 1b hepatitis C virus isolate cloned from a patient who underwent liver transplantation. <i>PLoS ONE</i> , 2011 , 6, e23587	3.7	11
134	Antiviral therapy in HCV decompensated cirrhosis: to treat or not to treat?. <i>Journal of Hepatology</i> , 2007 , 46, 185-8	13.4	11
133	Decompensation in Advanced Nonalcoholic Fatty Liver Disease May Occur at Lower Hepatic Venous Pressure Gradient Levels Than in Patients With Viral Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	11
132	Early non-invasive selection of patients at high risk of severe hepatitis C recurrence after liver transplantation. <i>Transplant Infectious Disease</i> , 2016 , 18, 471-9	2.7	11
131	Early HCV viral kinetics under DAAs may optimize duration of therapy in patients with compensated cirrhosis. <i>Liver International</i> , 2019 , 39, 826-834	7.9	11
130	Efficacy, safety, and pharmacokinetics of simeprevir, daclatasvir, and ribavirin in patients with recurrent hepatitis C virus genotype 1b infection after orthotopic liver transplantation: The Phase II SATURN study. <i>Transplant Infectious Disease</i> , 2017 , 19, e12696	2.7	10
129	Shorter hepatitis B immunoglobulin administration is not associated to hepatitis B virus recurrence when receiving combined prophylaxis after liver transplantation. <i>Liver International</i> , 2018 , 38, 1940-1950	7.9	10
128	Low dose alpha interferon therapy can be effective in chronic active hepatitis C. Results of a multicentre, randomised trial. <i>Gut</i> , 1996 , 38, 603-9	19.2	10
127	Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing Agents. <i>American Journal of Gastroenterology</i> , 2016 , 111, 845-51	0.7	10
126	Guidelines on treatment of hepatitis C virus infection. Spanish Association for the Study of the Liver (AEEL). <i>Gastroenterología Y Hepatología</i> , 2018 , 41, 597-608	0.9	10
125	Host phosphatidic acid phosphatase lipin1 is rate limiting for functional hepatitis C virus replicase complex formation. <i>PLoS Pathogens</i> , 2018 , 14, e1007284	7.6	10

124	Role of ITPA and SLC28A2 genes in the prediction of anaemia associated with protease inhibitor plus ribavirin and peginterferon in hepatitis C treatment. <i>Journal of Clinical Virology</i> , 2015 , 68, 56-60	14.5	9
123	Hepatitis C virus infection inhibits P-body granule formation in human livers. <i>Journal of Hepatology</i> , 2015 , 62, 785-90	13.4	9
122	Characterization of the cross-neutralizing antibody response against hepatitis C virus in the liver transplantation setting. <i>American Journal of Transplantation</i> , 2011 , 11, 767-74	8.7	9
121	MR elastography to assess liver fibrosis. <i>Radiology</i> , 2008 , 247, 591; author reply 591-2	20.5	9
120	Amyotrophic lateral sclerosis in a patient with systemic lupus erythematosus. <i>Lupus</i> , 1993 , 2, 133-4	2.6	9
119	Off-therapy response after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B: An international, multi-center, multi-ethnic cohort (RETRACT-B study). <i>Gastroenterology</i> , 2021 ,	13.3	9
118	Extrahepatic manifestations associated with Chronic Hepatitis C Virus Infection. <i>Revista Española De Sanidad Penitenciaria</i> , 2017 , 19, 87-97	0.4	9
117	Challenges in Special Populations: HIV/HCV Coinfection, Liver Transplantation and Patients with End-Stage Renal Disease. <i>Digestive Diseases</i> , 2016 , 34, 317-26	3.2	9
116	High efficacy of Sofosbuvir plus Simeprevir in a large cohort of Spanish cirrhotic patients infected with genotypes 1 and 4. <i>Liver International</i> , 2017 , 37, 1823-1832	7.9	8
115	Fine-mapping butyrophilin family genes revealed several polymorphisms influencing viral genotype selection in hepatitis C infection. <i>Genes and Immunity</i> , 2015 , 16, 297-300	4.4	8
114	Imaging of hepatitis C virus infection in liver grafts after liver transplantation. <i>Journal of Hepatology</i> , 2013 , 59, 271-8	13.4	8
113	Evolution of the NS3 and NS5B regions of the hepatitis C virus during disease recurrence after liver transplantation. <i>American Journal of Transplantation</i> , 2007 , 7, 2172-9	8.7	8
112	Quasispecies dynamics in hepatitis C liver transplant recipients receiving grafts from hepatitis C virus infected donors. <i>Journal of General Virology</i> , 2015 , 96, 3493-3498	4.9	8
111	Higher seroprevalence of hepatitis E virus in autoimmune hepatitis: Role of false-positive antibodies. <i>Liver International</i> , 2020 , 40, 558-564	7.9	8
110	Incidence of depression in patients with hepatitis C treated with direct-acting antivirals. <i>Revista Brasileira De Psiquiatria</i> , 2020 , 42, 72-76	2.6	8
109	Significant decrease in the prevalence of hepatitis C infection after the introduction of direct acting antivirals. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020 , 35, 1570-1578	4	7
108	Systematic review with meta-analysis: neuroimaging in hepatitis C chronic infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 47, 1238-1252	6.1	7
107	Hepatitis C virus early kinetics and resistance-associated substitution dynamics during antiviral therapy with direct-acting antivirals. <i>Journal of Viral Hepatitis</i> , 2018 , 25, 1515-1525	3.4	7

106	Graft and viral outcomes in retransplantation for hepatitis C virus recurrence and HCV primary liver transplantation: a case-control study. <i>Clinical Transplantation</i> , 2014 , 28, 821-8	3.8	7
105	Hemodynamic response to propranolol in patients with recurrent hepatitis C virus-related cirrhosis after liver transplantation: a case-control study. <i>Liver Transplantation</i> , 2013 , 19, 450-6	4.5	7
104	The extrahepatic contribution to HCV plasma viremia. <i>Journal of Hepatology</i> , 2006 , 45, 626-7; author reply 627-8	13.4	7
103	Evaluation of commercially available and in-house reverse transcription-PCR assays for detection of hepatitis G virus or GB virus C. <i>Journal of Clinical Microbiology</i> , 1997 , 35, 2698-702	9.7	7
102	Value of duplex-doppler ultrasound findings in liver transplant recipients with poor graft function. <i>Transplantation</i> , 1996 , 61, 832-5	1.8	7
101	Hepatitis C-related cirrhosis will be a marginal cause of hospital admissions by 2025. <i>Journal of Hepatology</i> , 2020 , 73, 1360-1367	13.4	7
100	P0779 : Ledipasvir/sofosbuvir with ribavirin for the treatment of fibrosing cholestatic hepatitis C after liver transplantation. <i>Journal of Hepatology</i> , 2015 , 62, S623	13.4	6
99	Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: the International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program. <i>Journal of Viral Hepatitis</i> , 2015 , 22, 469-80	3.4	6
98	Reply to "Direct antiviral agents and risk for hepatocellular carcinoma (HCC) early recurrence: Much ado about nothing". <i>Journal of Hepatology</i> , 2016 , 65, 864-865	13.4	6
97	Efficacy of new direct acting antivirals in transplant recipients and patients with advanced disease. <i>Digestive and Liver Disease</i> , 2014 , 46 Suppl 5, S197-205	3.3	6
96	A Gaussia luciferase cell-based system to assess the infection of cell culture- and serum-derived hepatitis C virus. <i>PLoS ONE</i> , 2012 , 7, e53254	3.7	6
95	Performance of hepatitis C virus core antigen immunoassay in monitoring viral load after liver transplantation. <i>Transplantation</i> , 2005 , 79, 1441-4	1.8	6
94	Aberrant integration of Hepatitis B virus DNA promotes major restructuring of human hepatocellular carcinoma genome architecture. <i>Nature Communications</i> , 2021 , 12, 6910	17.4	6
93	Viral eradication and fibrosis resolution in post-liver transplant cholestatic hepatitis C virus. <i>Liver Transplantation</i> , 2018 , 24, 703-707	4.5	5
92	Aplastic anemia and severe pancytopenia during treatment with peg-interferon, ribavirin and telaprevir for chronic hepatitis C. <i>World Journal of Gastroenterology</i> , 2015 , 21, 5421-6	5.6	5
91	Molecular epidemiology in HCV-related hepatocellular carcinoma: first steps. <i>Journal of Hepatology</i> , 2012 , 57, 213-4	13.4	5
90	Evaluation of a portable hemoglobinometer (HemoCue) to control anemia in hepatitis C liver transplant recipients undergoing antiviral therapy. <i>European Journal of Gastroenterology and Hepatology</i> , 2011 , 23, 942-7	2.2	5
89	Expected developments in hepatology. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , 2002 , 16, 957-70	2.5	5

88	Mericitabine and Either Boceprevir or Telaprevir in Combination with Peginterferon Alfa-2a plus Ribavirin for Patients with Chronic Hepatitis C Genotype 1 Infection and Prior Null Response: The Randomized DYNAMO 1 and DYNAMO 2 Studies. <i>PLoS ONE</i> , 2016 , 11, e0145409	3.7	5
87	Association of chronic inflammation and perceived stress with abnormal functional connectivity in brain areas involved with interoception in hepatitis C patients. <i>Brain, Behavior, and Immunity</i> , 2019 , 80, 204-218	16.6	4
86	LP24 : Safety, efficacy and impact on liver function of simeprevir (SMV) in combination with daclatasvir (DCV) or sofosbuvir (SOF) in patients with severe hepatitis C recurrence after liver transplantation (LT): results from compassionate use in europe. <i>Journal of Hepatology</i> , 2015 , 62, S275-S276	13.4	4
85	Cirrhosis Hampers Early and Rapid Normalization of Natural Killer Cell Phenotype and Function in Hepatitis C Patients Undergoing Interferon-Free Therapy. <i>Frontiers in Immunology</i> , 2020 , 11, 129	8.4	4
84	Portal Hypertension Reverses Following Successful Antiviral Treatment for HCV: Fact or Fiction?. <i>Current Hepatology Reports</i> , 2018 , 17, 209-217	1	4
83	O163 TURQUOISE-II: SVR12 RATES OF 92.6% IN 380 HEPATITIS C VIRUS GENOTYPE 1-INFECTED ADULTS WITH COMPENSATED CIRRHOSIS TREATED WITH ABT-450/R/ABT-267 AND ABT-333 PLUS RIBAVIRIN (3D+RBV). <i>Journal of Hepatology</i> , 2014 , 60, S523	13.4	4
82	Pretransplant and posttransplant treatment of hepatitis C virus infection with protease inhibitors. <i>Current Opinion in Organ Transplantation</i> , 2013 , 18, 271-8	2.5	4
81	Can we identify liver fibrosis in HCV-infected patients without a liver biopsy?. <i>Current Hepatitis Reports</i> , 2003 , 2, 145-151		4
80	Neutrophil and Monocyte Function in Patients with Chronic Hepatitis C Undergoing Antiviral Therapy with Regimens Containing Protease Inhibitors with and without Interferon. <i>PLoS ONE</i> , 2016 , 11, e0166631	3.7	4
79	Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEEL). <i>Revista Espanola De Enfermedades Digestivas</i> , 2019 , 111, 862-873	0.9	4
78	Simple prediction of long-term clinical outcomes in patients with mild hepatitis C recurrence after liver transplantation. <i>Transplant International</i> , 2016 , 29, 698-706	3	4
77	Severe hepatitis B reactivation during direct-acting antiviral treatment in "the absence" of hepatitis B surface antigen. <i>International Journal of Infectious Diseases</i> , 2019 , 79, 47-49	10.5	4
76	Clinical Trial Watch: Reports from the EASL International Liver Congress (ILC), Vienna, April 2015. <i>Journal of Hepatology</i> , 2015 , 63, 753-62	13.4	3
75	Reply to "Debilitating fatigue as a treatment indication in chronic hepatitis C". <i>Journal of Hepatology</i> , 2015 , 63, 1535-6	13.4	3
74	Externalized HCV linkage-to-care cascade in the biggest harm reduction center in Barcelona: approaching a high-risk PWID population. <i>Journal of Hepatology</i> , 2020 , 73, S360	13.4	3
73	Complete Remission of Hypertrophic Discoid Cutaneous Lupus Erythematosus After Treatment of Chronic Hepatitis C With Direct-Acting Antivirals. <i>JAMA Dermatology</i> , 2020 , 156, 471-472	5.1	3
72	Treatment of chronic hepatitis C. <i>Journal of Hepatology</i> , 2018 , 69, 544-546	13.4	3
71	Fanconi syndrome due to tenofovir disoproxil fumarate (TDF) after liver transplantation. <i>Digestive and Liver Disease</i> , 2019 , 51, 1352-1353	3.3	3

70	IFNL4 polymorphism predicts response to hepatitis C treatment after liver transplantation. <i>Journal of Clinical Virology</i> , 2014 , 61, 282-5	14.5	3
69	Aplastic Anemia and Severe Myelosuppression with Boceprevir or Simeprevir-Containing Hepatitis C Virus Treatment. <i>Annals of Hepatology</i> , 2017 , 16, 312-317	3.1	3
68	Hepatitis C treatment for patients post liver transplant. <i>Current Opinion in Organ Transplantation</i> , 2015 , 20, 251-8	2.5	3
67	Chronic hepatitis C, depression and gender: a state of art. <i>Advances in Dual Diagnosis</i> , 2015 , 8, 193-210	1.1	3
66	Viral hepatitis and liver transplantation: pathogenesis, prevention and therapy of recurrent disease. <i>Digestive Diseases</i> , 2014 , 32, 538-44	3.2	3
65	Nosocomial acquisition of the hepatitis C virus. <i>Journal of Hepatology</i> , 2008 , 48, 1020-1021	13.4	3
64	Advances in hepatitis C therapies. <i>Expert Opinion on Pharmacotherapy</i> , 2015 , 16, 1929-43	4	2
63	Severe Hepatitis C Recurrence as a Risk Factor for Opportunistic Infections in Liver Transplant Recipients. <i>Transplantation Proceedings</i> , 2018 , 50, 1437-1443	1.1	2
62	Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEEH). <i>Gastroenterología Y Hepatología (English Edition)</i> , 2019 , 42, 579-592	0.1	2
61	P219 FINE MAPPING OF THE BUTYROPHILIN GENOMICS REGION: ROLE IN HEPATITIS C VIRUS INFECTION (HCV). <i>Journal of Hepatology</i> , 2014 , 60, S139	13.4	2
60	Permissiveness of human hepatocellular carcinoma cell lines for hepatitis C virus entry and replication. <i>Virus Research</i> , 2017 , 240, 35-46	6.4	2
59	Analysis of serine codon conservation reveals diverse phenotypic constraints on hepatitis C virus glycoprotein evolution. <i>Journal of Virology</i> , 2014 , 88, 667-78	6.6	2
58	Interpreting liver stiffness in the cirrhotic range: What are we measuring?. <i>Journal of Hepatology</i> , 2009 , 50, 424-425	13.4	2
57	[33] HEPATITIS C VIRUS COMPARTMENTALIZATION AND INFECTION RECURRENCE AFTER LIVER TRANSPLANTATION. <i>Journal of Hepatology</i> , 2007 , 46, S16	13.4	2
56	Development of amyotrophic lateral sclerosis in the course of systemic lupus erythematosus. <i>Clinical Rheumatology</i> , 1992 , 11, 578-9	3.9	2
55	Low seroprevalence and zero incidence rate of hepatitis E in men who have sex with men during a hepatitis A outbreak. <i>Journal of Medical Virology</i> , 2020 , 92, 1359-1362	19.7	2
54	Improvement of sexuality after hepatitis C cure with direct acting antivirals. <i>Liver International</i> , 2020 , 40, 2972-2977	7.9	2
53	Chronic genotype 1 hepatitis C along with cirrhosis drives a persistent imprint in virus-specific CD8 T cells after direct-acting antiviral therapies. <i>Journal of Viral Hepatitis</i> , 2020 , 27, 1408-1418	3.4	2

52	Impact of Sexualized Substance Use and Other Risk Practices on HCV Microelimination in gbMSM Living with HIV: Urgent Need for Targeted Strategies. Results of a Retrospective Cohort Study. <i>Infectious Diseases and Therapy</i> , 2021 , 10, 1253-1266	6.2	2
51	Efficacy of an accelerated double-dose hepatitis B vaccine regimen in patients with cirrhosis. <i>Journal of Viral Hepatitis</i> , 2021 , 28, 1019-1024	3.4	2
50	Resolution of subclinical porphyria cutanea tarda after hepatitis C eradication with direct-acting anti-virals. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 51, 968-973	6.1	2
49	Influence of the genetic heterogeneity of the ISDR and PePHD regions of hepatitis C virus on the response to interferon therapy in chronic hepatitis C 2001 , 65, 35		2
48	Letter: hepatitis B reactivation in patients with chronic hepatitis C during direct-acting antiviral therapy-authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 45, 1559-1560	6.1	1
47	Ductular reaction and hepatocyte ballooning identify patients with fibrosing cholestatic hepatitis after liver transplantation. <i>Gastroenterología Y Hepatología</i> , 2020 , 43, 14-21	0.9	1
46	Hepatitis B Reactivation or Hepatitis C Exacerbation in Patients with Hematological Malignancies. <i>Annals of Hepatology</i> , 2017 , 16, 179-181	3.1	1
45	Noninvasive tests in the post-liver transplantation setting. <i>Liver Transplantation</i> , 2007 , 13, 628-629	4.5	1
44	The challenge of chronic hepatitis E in liver transplant recipients: Failure of sofosbuvir plus ribavirin therapy. <i>Gastroenterología Y Hepatología</i> , 2020 , 43, 136-137	0.9	1
43	Liver cancer risk after HCV cure in patients with advanced liver disease without non-characterized nodules. <i>Journal of Hepatology</i> , 2021 ,	13.4	1
42	Point-of-care hepatitis C testing and treatment strategy for people attending harm reduction and addiction centres for hepatitis C elimination. <i>Journal of Viral Hepatitis</i> , 2021 ,	3.4	1
41	The HBeAg-Negative "Gray Zone" Phase: A Frequent Condition With Different Outcomes in Western and Asian Patients?. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 263-264	6.9	1
40	Reply to: "The reported 'clear cut time association between interferon-free treatment and HCC' is anything but clear cut". <i>Journal of Hepatology</i> , 2020 , 72, 1036-1037	13.4	1
39	Red yeast rice extract: The risky trend of natural products. <i>Gastroenterología Y Hepatología</i> , 2021 , 44, 293-294	0.9	1
38	Safety of Patients with Hepatitis C Virus Treated with Glecaprevir/Pibrentasvir from Clinical Trials and Real-World Cohorts. <i>Advances in Therapy</i> , 2021 , 38, 3409-3426	4.1	1
37	HCVerso3: An Open-Label, Phase IIb Study of Faldaprevir and Deleobuvir with Ribavirin in Hepatitis C Virus Genotype-1b-Infected Patients with Cirrhosis and Moderate Hepatic Impairment. <i>PLoS ONE</i> , 2016 , 11, e0168544	3.7	1
36	Risk of non-tumoural portal vein thrombosis in patients with HCV-induced cirrhosis after sustained virological response. <i>Liver International</i> , 2021 ,	7.9	1
35	Efficacy of telaprevir-based therapy in stable liver transplant patients with chronic genotype 1 hepatitis C. <i>Annals of Hepatology</i> , 2016 , 15, 512-23	3.1	1

34	Efficacy and safety of direct-acting antivirals in older patients with cirrhosis and high comorbidity index. <i>European Journal of Gastroenterology and Hepatology</i> , 2020 , 32, 389-394	2.2	○
33	Antiviral therapy in HCV-infected cirrhotic patients awaiting liver transplantation. <i>Journal of Hepatology</i> , 2009 , 51, 960-962	13.4	○
32	Hepatitis C virus intrinsic molecular determinants may contribute to the development of cholestatic hepatitis after liver transplantation. <i>Journal of General Virology</i> , 2019 , 100, 63-68	4.9	○
31	Elastography is unable to exclude cirrhosis after sustained virological response in HCV-infected patients with advanced chronic liver disease. <i>Liver International</i> , 2021 , 41, 2733-2746	7.9	○
30	Primary herpes simplex virus type 1 infection with acute liver failure in solid organ transplantation: Report of three cases and review.. <i>IDCases</i> , 2022 , 28, e01485	2	○
29	Juan Rod�, M.D., Ph.D. (1938-2017): Excellence and leadership. <i>Hepatology</i> , 2017 , 65, 2137-2138	11.2	
28	Reply to: "Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules - A response". <i>Journal of Hepatology</i> , 2019 , 71, 447-448	13.4	
27	Ductular reaction and hepatocyte ballooning identify patients with fibrosing cholestatic hepatitis after liver transplantation. <i>Gastroenterolog� Y Hepatolog� (English Edition)</i> , 2020 , 43, 14-21	0.1	
26	Reply to: "Extended DAA indications for hepatitis C patients awaiting liver transplantation and further statistical considerations". <i>Journal of Hepatology</i> , 2018 , 68, 627-628	13.4	
25	Massive hemolysis complicating acute granulomatous hepatitis. <i>Annals of Hematology</i> , 2018 , 97, 1741-1742	3.42	
24	Reply. <i>Gastroenterology</i> , 2018 , 154, 1551-1552	13.3	
23	An uncommon presentation of alcoholic liver disease. <i>Liver International</i> , 2018 , 38, 1514	7.9	
22	Cost-Effectiveness Analysis Of Triple Therapy With Peginterferon, Ribavirin, And Boceprevir For The Treatment Of Chronic Hepatitis C Virus Genotype 1 With Severe Fibrosis Under "Real-Life" Conditions. <i>Value in Health</i> , 2014 , 17, A367	3.3	
21	THU0298 Are Anti-La Antibodies A Potential Protection for Hepatitis C Virus Infection in Sj�gren Syndrome? Analysis in 663 Patients. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 286.2-286	2.4	
20	Proton-pump inhibitors and glecaprevir plus pibrentasvir in HCV infection - Authors' reply. <i>Lancet Infectious Diseases, The</i> , 2017 , 17, 1240	25.5	
19	Extrahepatic Manifestations in Patients With Chronic Hepatitis C Virus Infection. <i>Handbook of Systemic Autoimmune Diseases</i> , 2017 , 13, 173-202	0.3	
18	P14: HepatiC, the viral hepatitis C patients management application and database. <i>Journal of Viral Hepatitis</i> , 2013 , 20, 23-24	3.4	
17	Reply: To PMID 21294144. <i>Hepatology</i> , 2013 , 57, 855	11.2	

- 16 Role of nosocomial hospital transmission in acute hepatitis C: Reply. *Journal of Hepatology*, **2009**, 50, 214 13.4
- 15 Tratamiento de mantenimiento. *Gastroenterología Y Hepatología*, **2006**, 29, 180-183 0.9
- 14 Considerations for optimizing Wilson's disease patients' long-term follow-up. *Gastroenterología Y Hepatología (English Edition)*, **2022**, 45, 146-146 0.1
- 13 Cirrosis por el virus de la hepatitis C **2008**, 357-368
- 12 Primary Sjögren's Syndrome and Viruses **2011**, 55-66
- 11 Assessing the Progression of Chronic HCV to Cirrhosis **2012**, 21-33
- 10 Genotypes 2 and 3 Relapse and Non-Response 104-112
- 9 Chronic viral hepatitis C 610-617
- 8 Treatment of Hepatitis C Before Liver Transplantation **2014**, 1-14
- 7 Reply to: Optimal hepatitis B vaccination schedule for cirrhotic patients: a still unanswered question. *Journal of Viral Hepatitis*, **2021**, 28, 1331-1332 3.4
- 6 Contributing awareness of autoimmune hepatitis in HIV patients. *Aids*, **2019**, 33, 2103-2105 3.5
- 5 Simplified follow-up of patients with mild chronic hepatitis C in areas with limited access to antiviral therapy. *Digestive and Liver Disease*, **2019**, 51, 875-881 3.3
- 4 Guidelines on treatment of hepatitis C virus infection. Spanish Association for the Study of the Liver (AEEH). *Gastroenterología Y Hepatología (English Edition)*, **2018**, 41, 597-608 0.1
- 3 Hepatitis C therapy and anticonvulsants. *Gastroenterología Y Hepatología (English Edition)*, **2021**, 44, 536 0.1
- 2 Hepatitis C therapy and anticonvulsants. *Gastroenterología Y Hepatología*, **2021**, 44, 536 0.9
- 1 Recurrent Disease and Management in Liver Transplantation 2010-2018